In June, Lipigon Pharmaceuticals signed a development and licensing agreement worth nearly SEK 1 billion. Today, the Umeå-based company has relocated to a newly renovated 250 square meter facility tailored to their needs. Lipigon's CEO, Stefan K. Nilsson, views these achievements as "pivotal strides in the company's ongoing journey of growth and innovation."
Umeå-based Lipigon Pharmaceuticals is celebrating the signing of a development and license agreement for its clinical-stage drug candidate Lipisense® with Leaderna Therapeutics worth an estimated USD 91 million.
A new share issue in Umeå-based Lipigon Pharmaceuticals that was issued ahead of a listing on the Nasdaq First North Growth Market has exceeded all expectations. The listing was oversubscribed by 479 per cent, raising SEK 235 million spread over more than 9,000 investors.
Lipigon Pharmaceuticals AB, which develops new treatments for lipid-related diseases, announces that the board has elected Urban Paulsson as the new chairman of the board. Paulsson was elected to the board on October 30, 2020 and now replaces Carina Schmidt, who requested her own resignation from the board.
At an Extraordinary General Meeting, Urban Paulsson was elected a regular board member of Umeå-based Lipigon Pharmaceuticals AB. Urban Paulsson's business law expertise entails a strengthening of the Board and is an important component for the company's continued successful development.
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.
Tvistevägen 48C
907 36 Umeå
Sweden